Mainz Biomed (MYNZ) - צמיחה צפויה ברווח למניה לשנה הבאה

Mainz Biomed N.V. (MYNZ) - לוגו תאגידי

Mainz Biomed N.V. is developing non-invasive colorectal cancer diagnostics, diversifying across US and European markets. The forward EPS forecast for the coming year is derived from the GURU.Markets chart, where 98.70 represents the current metric. This confirms the company's ESG status by reducing bio-waste and strictly adhering to medical regulations regarding chemical disposal in laboratories.

mainzbiomed.com (MYNZ): תחזית קונצנזוס לצמיחת רווח למניה לשנה הבאה מ-04.07.2022 עד 11.03.2026

MYNZ (Mainz Biomed NV): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- מחיר ותחזית קונצנזוס למחירים:
ניתוח מקיף של החברה:mainzbiomed.com, MYNZ
מוצר עיקרי של Mainz Biomed

The positive trend in the forward net income growth rate reflects market confidence in the commercialization of Mainz Biomed N.V. (MYNZ) non-invasive tests in Europe and the US. This indicator measures the percentage change in expected earnings per share (EPS) for the following year, allowing investors to assess the fundamental resilience of the business and adjust their entry strategy for the asset in a timely manner.